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Abstract
Mitochondria are organelle, which is found in most eukaryotic cells, and play an im‐
portant roll in production of many biosynthetic intermediates as well as energy trans‐
duction. Recently, it has been reported that mitochondria contribute to cellular stress
responses such as apoptosis and autophagy. These functions of mitochondria are
known to be essential for survival and maintenance of homeostasis. The mitochondria
of malaria parasites are quite different from those of their vertebrate hosts. Because
these differences markedly contribute to drug selectivity, we have focused on the Plas‐
modium mitochondrion to develop antimalarial drugs. Here we summarize recent ad‐
vances in our knowledge of the mitochondria of malaria parasites and discuss future
prospective antimalarial drugs targeting the parasite mitochondrion.
Keywords: malaria, Plasmodium, mitochondria, antimalarial drugs, atovaquone, 5-
aminolevulinic acid
1. Introduction
Malaria is a major global health problem, shortening over 500,000 human lives annually,
mainly children in tropical and subtropical regions [1]. Due to difficulties in developing
antimalarial vaccine, chemotherapy is important for controlling malaria. Parasites causing
malaria, however, can rapidly develop resistance against the available chemotherapies [2].
Thus, new drugs with different modes of action are urgently needed. Malaria parasites are
disseminated by female Anopheles mosquitoes and belong to the Plasmodium genus. Plasmodi‐
um has a complicated life cycle, comprising two major cycles: asexual multiplication in humans
and sexual multiplication in mosquitoes (Figure 1) [3]. The parasites invade the hepatocytes
of their host and mature into merozoites. After release, the merozoites infect red blood cells
(RBCs). In the RBCs, the parasites differentiate into the following stages: ring, trophozoite, and
schizont. Subsequently, the infected RBCs burst and release merozoites, which invade
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uninfected RBCs. These stages are called the erythrocytic stages, where the parasites multiply
asexually. Following the establishment of infection, some parasites differentiate to gameto‐
cytes [4]. The gametocyte stage is essential for subsequent transmission because this is the only
stage where the organism undergoes sexual development in the mosquito vector. Therefore,
Plasmodium has a complex life cycle, which seems to be an adaptation to its host environment
[5]. In addition to the complex life cycle, the malaria parasites have evolved sophisticated
pathways of energy transduction to adapt to their hosts.
Figure 1. Life cycle of the human malaria parasite Plasmodium falciparum.
Mitochondria, an organelle arising from alpha-proteobacterium engulfed by a eukaryotic
progenitor [6], play a key role in energy transduction of eukaryotic cells. In vertebrates, that
can become a host for malaria parasites, mitochondria have been reported to contribute to
cellular responses such as autophagy, apoptosis, and ATP production [7]. The vertebrate
mitochondrion comprises two separate and functionally distinct outer and inner membranes
that form cristae, and it also contains its own circular genome, the mitochondrial genome
(mtDNA). With few exceptions, vertebrate mtDNA is approximately 16 kb in size, encoding
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37 genes: two for ribosomal RNAs (rRNAs), 13 for proteins, and 22 for tRNAs [8]. In contrast
to the vertebrate mitochondrion, the Plasmodium mitochondrion is a single tubular organelle
structure [9] that possesses a 6-kb mtDNA, encoding only three genes for proteins and highly
fragmented rRNA genes [10], and it is the smallest eukaryotic mtDNA. Furthermore, the
erythrocytic stages of the parasite have been considered to mainly rely on glycolysis, with
secretion of end products such as lactate and pyruvate [11, 12]. The mitochondria of malaria
parasites are thus quite different from those of their vertebrate hosts. Because these differences
markedly contribute to drug selectivity, we have focused on the Plasmodium mitochondrion
to develop antimalarial drugs. Here we summarize recent advances in our knowledge of the
mitochondria of malaria parasites and discuss future prospective antimalarial drugs targeting
the parasite mitochondrion.
2. Biochemical functions of malaria parasite mitochondria
2.1. ATP production in canonical eukaryotes
Conventionally, a mitochondrion is the cell’s powerhouse, in which energy stored in chemical
bonds is turned into ATP via oxidative phosphorylation. ATP production can be divided into
three pathways: glycolysis, mitochondrial tricarboxylic acid (TCA) cycle, and mitochondrial
electron transport chain (mtETC). Glycolysis breaks down one molecule of glucose into two
molecules of pyruvate, generating two molecules of ATP. Pyruvate then moves into the
mitochondrion where it is converted to acetyl-CoA and carbon dioxide by pyruvate dehydro‐
genase complex (PDH). Subsequently, acetyl-CoA enters the TCA cycle. The mtETC involves
the passage of electrons from TCA-cycle NADH or from succinate via mtETC complexes to
oxygen, with concomitant translocation of protons into the mitochondrial intermembrane
space. Generally, the mtETC comprises four integral membrane enzyme complexes in the
mitochondrial inner membrane: NADH-ubiquinone oxidoreductase (complex I), succinate-
ubiquinone oxidoreductase (SQR, complex II), ubiquinol-cytochrome c oxidoreductase
(complex III or cytochrome bc1), and cytochrome c oxidase (complex IV). Ubiquinone (Q) and
cytochrome c (complex IV) function as electron carriers and the complexes I, III, and IV function
as sites generating potential. The resultant potential across the mitochondrial inner membrane
is used to drive ATP synthesis.
2.2. ATP production in malaria parasites
Similar to canonical eukaryotes, in the mosquito stages of malaria parasites, the organisms
produce ATP in their mitochondria [13]. In the erythrocytic stages, however, the mitochondrial
energy transduction system for oxidative phosphorylation is downregulated to adapt to host
environments and produce ATP mainly via glycolysis using blood glucose [14, 15]. As a
consequence, in malaria parasite-infected patients, plasma lactate levels tend to be high and
highly variable, ranging from 2 to 26.7 mM [16, 17], compared with plasma lactate levels (0.3-1.3
mM) in normal individuals. Apart from the minor flux of carbon backbone derived from
glucose, TCA metabolism of Plasmodium was believed to involve a branched architecture
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bifurcating from 2-oxoglutarate until recently [18]; however, this report was subsequently
retracted [19]. More recently, the malaria parasites have been reported to use the canonical
oxidative mitochondrial TCA cycle to catabolize host glucose and glutamate (Figure 2) [20],
even during asexual multiplication. The TCA cycle begins with malate generated by anapler‐
otic reactions and 2-oxoglutarate produced from glutamine as well as conversion of acetyl-
CoA to citrate by citrate synthase [20-22]. In general, pyruvate, the end product of glycolysis,
is transported via the monocarboxylate transporter (MCT) family [23]. Plasmodium possesses
two MCT genes (PF3D7_0210300 and PF3D7_0926400) identified in its genome (PlasmoDB
version 11.0, website: http://plasmadb.org/plasma/). Although further evidence is required,
these MCTs are considered to be associated with the transport of pyruvate across the mito‐
chondrial membrane [24]. To convert pyruvate into acetyl-CoA, Plasmodium retains branched
chain ketoacid dehydrogenase (BCKDH), the only enzyme implicated in branched chain
amino acid degradation [22]. PDH complex, linking cytoplasmic glycolysis to the TCA cycle
in canonical eukaryotes, is not localized to the mitochondrion but to a plastid, apicoplast, in
Plasmodium [25]. The function of the Plasmodium PDH complex seems to include the provision
of acetyl-CoA for de novo fatty acid synthesis within the apicoplast.
Figure 2. TCA cycle and oxidative phosphorylation of malaria parasites. The TCA cycle of malaria parasites begins
with malate, 2-oxoglutarate, and citrate [20-22].
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In the Plasmodium TCA cycle, succinate and malate are oxidized by SQR and malate-ubiqui‐
none oxidoreductase (MQO), respectively, with transporting electrons to the matrix [26]
(Figure 2). Similar to SQR of most eukaryotes, the Plasmodium SQR comprises four polypep‐
tides: a flavoprotein (Fp) subunit, iron-sulfur (Ip) subunit [27], and two cytochrome b (cytb)
subunits (CybL and CybS) [28]. Fp and Ip form the catalytic portion of the complex. This
portion acts as a succinate dehydrogenase (SDH), catalyzing the oxidation of succinate by
water-soluble electron acceptors such as phenazine methosulfate in SQR, and is bound to the
matrix side of the mitochondrial inner membrane via the membrane-anchoring proteins CybL
and CybS. Because the mitochondria of erythrocytic stage parasites show both SQR and SDH
activities [27, 29, 30], complex II has been considered to have some role in parasite survival.
These activities, however, are very low, compared with those of the other eukaryotes (Table
1) [31-35]. Furthermore, our previous studies have demonstrated that disruption of the Fp
subunit genes pfsdha and Pbsdha does not affect growth in the erythrocytic stages in vitro [36]
and in vivo [37], respectively. These findings reveal that complex II is not essential for survival
of the erythrocytic stage parasites, and this appears to be associated with relatively low
activities of SQR and SDH in these developmental stages.
*Activity values of P. falciparum, T. cruzi, A. suum, rat liver, bovine heart, and human cell are obtained from references [29,
31, 32, 33, 34], and [35], respectively.
Table 1. Specific activities of succinate-ubiquinone oxidoreductase of various organisms
MQO is an FAD-dependent membrane-associated protein that catalyzes the oxidation of
malate to oxaloacetate [38]. The electrons are donated to quinones of the mtETC, and NAD is
accepted as an electron donor. The MQO has been not observed in mammals but has been
found in Plasmodium [39] and some bacteria [40]. This implies that the Plasmodium MQO could
be a target for drug design. In addition to SQR and MQO in the TCA cycle, Plasmodium
possesses three oxidoreductases in its mitochondrial inner membrane: type II NADH:ubiqui‐
none oxidoreductase (NDH2) [41], dihydroorotate dehydrogenase (DHODH) [42, 43], and
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) [44, 45], all of which can reduce
ubiquinone (Figure 2). Unlike the large multisubunit complex I in most mitochondria, the
Plasmodium NDH2 is a single subunit enzyme, not involved in the direct pumping of protons
across the membrane [46]. The absence of NDH2 in mammalian mitochondria shows that this
enzyme would be a promising target of a novel antimalarial drug. Some antimalarial activities
of NDH2 inhibitors, such as HQNO [47] and 1-hydroxy-2-dodecyl-4(1H) quinolone [48], have
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been reported. However, a recent in vivo study on Plasmodium berghei revealed that the
Plasmodium NDH2 could be deleted by targeted gene disruption, indicating that it is dispen‐
sable in the erythrocytic stages [49]. This disproves that NDH2 is a candidate drug target. Thus,
the potential of targeting NDH2 as an antimalarial drug remains controversial.
The other dehydrogenases (DHODH and G3PDH) transfer electrons from reduced com‐
pounds in the cytosol (Figure 2). In the erythrocytic stages of the parasite, DHODH plays two
roles—a generator of reduced ubiquinone and the fourth enzyme in the pyrimidine biosyn‐
thetic pathway. Since Plasmodium cannot salvage pyrimidine [50], DHODH is essential for its
survival [42]. Therefore, in the erythrocytic stages, the mtETC appears to be essential for the
pyrimidine biosynthetic pathway rather than for contributing to the ATP pool [11].
As presented above, in Plasmodium mitochondria, five mitochondrial dehydrogenases (SQR,
MQO, NDH2, DHODH, and G3PDH) can generate reduced ubiquinone, which in turn is
reoxidized by cytochrome bc1 complex (complex III). Complex III is inhibited by atovaquone
[51], which collapses the mitochondrial membrane potential [52]. As an antimalarial, atova‐
quone is very effective; however, atovaquone-resistant parasites develop easily. Mechanisms
of atovaquone resistance are described in Section 4. Similar to canonical eukaryotes, Plasmo‐
dium utilizes cytochrome c (cytc) as electron carriers and complexes III and IV as sites gener‐
ating potential. The resultant potential across the mitochondrial inner membrane is used to
drive ATP synthesis. Plasmodium ATP synthase is markedly different from that of its host [53]
—it is assembled as a large dimeric complex in the erythrocytic stages. In the ciliates Tetrahy‐
mena thermophila and Paramecium, the structure and arrangement of dimeric ATP synthase have
been suggested to determine the tubular morphology of the mitochondrial cristae [54, 55]. This
could explain how the tubular cristae found in the mitochondria of erythrocytic stages are
generated.
2.3. Mitochondrial energy metabolism: a target of antimalarial drugs
Recently, in addition to the genetic disruptions of SDH and NDH2 described above, it has been
reported that six TCA cycle enzymes can be genetically disrupted in the erythrocytic stage or
sexual development stage [45]. These reports suggest that the TCA cycle would not be essential
for survival in these developmental stages. Hence, to develop an antimalarial drug, promising
mitochondrial targets would be DHODH, which is associated with the pyrimidine biosynthe‐
sis pathway and mtETC, and the mitochondrial complexes III, IV, and V that generate electron
gradients on the mitochondrial inner membrane.
On the other hand, it has been recently demonstrated that parasites derived directly from
infected patients show three distinct gene expression states. One of these states demonstrates
that the expression levels of the TCA cycle- or mtETC-related genes are increased [56].
Furthermore, mice infected with P. berghei or Plasmodium yoelii perform active oxidative
phosphorylation [57], suggesting that, in some physiological conditions, malaria parasites may
produce ATP via the mitochondrial TCA cycle and mtETC. Thus, we cannot exclude the
possibility that all the mitochondrial enzymes are potential targets for antimalarial drugs.
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3. The mitochondrial genome of malaria parasites
Malaria parasites possess a mitochondrial genome in the form of circular and/or tandemly
repeated linear elements of 6 kb, the smallest in size among eukaryotic cells [58]. Copy numbers
for this element are approximately 20-fold and 150-fold of the nuclear genomes in the human
malaria parasite Plasmodium falciparum [58] and the rodent malaria parasite P. yoelii [59],
respectively. These differences in the copy number may reflect differences in oxidative
phosphorylation activities as noted previously (see Section 2.3). The 6-kb element contains
only three mitochondrial protein-coding genes in addition to the large subunit (LSU) and small
subunit (SSU) rRNA genes [60, 61, 62] (Figure 3). The three protein-coding genes are cytc
oxidase subunit 1 (cox1) and subunit 3 (cox3), members of the cytc oxidase complex (complex
IV), and cytb (cob), a member of cytochrome bc1 complex. In all eukaryotic cells possessing
mitochondria, cox1 and cob are encoded by the mitochondrial genome. Because the organisms
possessing mitochondrion-like organelles without its own DNA (e.g., hydrogenosome and
mitosome) do not have cox1 and cob, these two genes appear to be essential for maintenance
of the mtETC.
Figure 3. Mitochondrial (mt) genome structure of malaria parasites. Mt-genome organization is perfectly conserved
among 23 Plasmodium species [63]. Elements within the mt genome of Plasmodium are tandemly repeated, so the desig‐
nation of both termini is arbitrary. Light green and light magenta boxes indicate fragments of LSU and SSU rRNA
genes, respectively.
The two rRNA genes of the Plasmodium mitochondrial genome are highly fragmented [63],
and the fragmentation is the most extreme example of any described rRNA fragmentation.
Recently, transcription of almost all intergenic regions of the Plasmodium mitochondrial
genome has been demonstrated [63]. The results show that 27 small rRNA fragments (12 SSU
rRNAs and 15 LSU rRNAs), ranging from 23 to 190 nt, are present in its mitochondrial genome
(Figure 4). All the rRNAs are predicted to pair with at least one of the other rRNA, creating
interactions that would help maintain the appropriate location and orientation of each rRNA.
Notably, among the Plasmodium genera, the nucleotide sequences of noncoding regions, as
well as fragmented rRNA gene regions, are more conserved when compared with those of the
protein-coding gene regions [10]. It thus appears that these highly conserved sequence regions
code for functional RNAs, including additional fragmented rRNAs.
In addition to the highly fragmented rRNAs, the mitochondria of malaria parasites have a
unique property—transfer RNA (tRNA) is absent; therefore, protein translation in the
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mitochondrion was to date considered as being impossible. However, recently, extramito‐
chondrial phenylalanyl-tRNA synthesis has been found in mitochondria of the erythrocytic
stages, suggesting that the parasite mitochondrion can import tRNAs from the cytoplasmic
tRNA pool [64]. These findings referring to the parasite rRNAs and tRNAs would make the
parasite mitochondrial protein translation a desirable organelle to target as an antimalarial
drug.
In malaria parasites, mtDNA is replicated via rolling circle replication to generate the linear
concatemers, similar to the replication mechanism used by some bacteriophages and plasmids
[58]. This replication manner is remarkably different from that of the vertebrate mtDNA, which
is replicated by a theta mechanism. Furthermore, mitochondrial DNA polymerase, which has
been characterized as a γ-like DNA polymerase, is strongly resistant to 2,3-dideoxythymi‐
dine-5-triphosphate and, in this aspect, differs from its vertebrate homolog [65], suggesting
structural differences between the Plasmodium and vertebrate DNA polymerase. Further
research on translation and replication mechanisms of the parasite mtDNA may help identify
potential targets for drug candidates.
4. Atovaquone resistance in malaria parasites
4.1. Predicted mode of action for atovaquone
Atovaquone (a hydroxy-1,4-naphthoquinone derivative) is a broad-spectrum antiparasitic
agent active against malaria, Pneumocystis carinii pneumonia, toxoplasmosis, and babesiosis
[66]. The mode of action for atovaquone involves selective inhibition of parasite mtETC
Figure 4. Fragmentation of the mitochondrial LSU and SSU rRNA genes of Plasmodium falciparum. Red line indicates
rRNA regions. Purple lines indicate recently identified additional fragmented rRNA candidates[63].
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without affecting the host mitochondrial functions at effective doses, making it the first
member of an entirely new class of antimalarial agents [52]. This drug shares structural
similarity with ubiquinone, a coenzyme involved in mtETC and serves as a point of contact
between energy metabolism and pyrimidine metabolism. Therefore, a potential molecular
target of atovaquone can be the ubiquinol oxidation pocket, Qo site, of the cytochrome bc1
complex [51, 67] because it may have a specific inhibitory effect on the parasite cytochrome bc1
complex. Generally, the cytochrome bc1 complex is a structural and functional homodimer.
The catalytic core comprises three redox active subunits, cyt b with two b-type hemes,
cytochrome c1 (cytc1) with a c-type heme, and Rieske protein with a [2Fe-2S] cluster [68].
Cytb catalyzes the transfer of electron from ubiquinol to cytc1, coupled to the transmembrane
proton translocation across the mitochondrial membrane [69]. There are two distinct catalytic
sites on the cytb protein, which are involved in the proton motive Q cycle and are proposed to
account for the electron transfer and proton translocating activity through the cytochrome bc1
complex: center o (also designated as Qo or center P) on the cytoplasmic site of the mitochon‐
drial inner membrane, where ubiquinol (QH2) oxidation occurs, and center i (Qi or center N)
on the matrix site, where ubiquinone (Q) reduction occurs. Because of its structural similarity
with ubiquinone, atovaquone appears to inhibit the cytochrome bc1 complex by competitive
binding with coenzyme Q for one of these sites.
4.2. Emergence of atovaquone-resistant malaria parasites
Atovaquone is majorly used for treatment and chemoprophylaxis of falciparum malaria for
international travelers [70], but the major problem is rapidity of emergence of drug resistance
when it is used as a single agent. Thus far, proguanil, which inhibits the parasite dihydrofolate
reductase, is combined with atovaquone to prevent the emergence. The combination drug,
registered as Malarone® (GlaxoSmithKline group of companies), is approved for treating
malaria in more than 30 countries and is used for chemoprophylaxis for international travelers.
However, atovaquone-resistant parasites isolated from malaria patients have also been highly
reported [71-73]. These studies demonstrate that atovaquone resistance is associated with point
mutations of the amino acid residue at codon 268 of cytb (Pfcob) constructing the cytochrome
bc1 complex. The mutations Y268S, Y268N, and Y268C have been found in atovaquone-
resistant parasites.
To mimic the situation of emergence of atovaquone-resistant parasites in a clinical setting, we
chose a mouse malaria model using BALB/c mice and the P. berghei ANKA strain. In the first
trial, we administered atovaquone intraperitoneally on seven consecutive days at doses
ranging from 0.4 μg/kg/day to 4.8 mg/kg/day and obtained P. berghei isolates with four genetic
resistance variations in cytb [74] (Table 2). We did not observe the mutation of the amino acid
residue at codon 268, which is observed in P. falciparum. The two mutations, M133I and L144S,
are located in Qo1, and these code amino acids are critical for inhibitor resistance in yeast and
mice [75, 76]. Moreover, in Plasmodium, the M133I and L144S amino acid changes appear to be
structurally significant, altering the conformational structure of the ubiquinone-binding site
and thus lowering the affinity of atovaquone to the Qo1 site. The mutation V284F is located in
the sixth transmembrane domain adjacent to the Qo2 site, and the amino acid change by itself
Mitochondria of Malaria Parasites as a Drug Target
http://dx.doi.org/10.5772/61283
25
confers only an approximately 10-fold resistance to atovaquone. Notably, the mutation V284F
has been found in all atovaquone-resistant clones [74].
Table 2. Mutations in the cytochrome b of Plasmodium berghei with atovaquone resistance
To obtain a better model for the biochemical and genetic studies of mutations found in P.
falciparum, we performed further experiments to obtain P. berghei strains, resistant to atova‐
quone, with mutations in the Qo2 region conferring high degrees of resistance [77]. The
parasite-infected mice were treated intraperitoneally for 3 consecutive days at a dose of 14.4
mg/kg/day, a higher dose than in the previous experiment. The results showed three variations
of the atovaquone-resistant mutation, including mutations at codon 268 (Y268N, Y268C, and
L271/K272R; Table 2). All the mutations were located in the Qo2 region, and these resistance
levels were more than 500 times higher than those of the wild type, although the resistance
levels of the previous isolates were more than 50 times higher. Administered doses of atova‐
quone affected the site of mutation in cytb and the level of drug resistance.
As described above, our group has reported various mutations in the quinone-binding sites
of the cytb gene of P. berghei, such as M133I, L144S, L271V, K272R, Y268C, Y268S, Y268N, and
V284F, using the mouse model with continuous atovaquone pressure. However, no direct
evidence of a relationship between the mutations and resistance has been observed using intact
mitochondria isolated from the malarial parasite, although biochemical analysis of the mutant
has been reported using cell-free extract [78]. To address this point, we have further investi‐
gated the activity of dihydroorotate-cytc reductase (regarding this mitochondrial pathway, see
Section 2) in both atovaquone-resistant and atovaquone-sensitive P. berghei isolates [79]. The
results showed that mutations in the quinone-binding site of the cytb gene resulted in variable
sensitivity to atovaquone and provided direct evidence for the atovaquone inhibitory mech‐
anism in the parasite cytochrome bc1 complex.
4.3. Cytochrome bc1 complex as an antimalarial drug target
Recently, the X-ray crystallographic structure of the mitochondrial cytochrome bc1 complex
from Saccharomyces cerevisiae with atovaquone has been resolved, and it demonstrates atova‐
quone bound in the Qo site [80]. It can therefore explain the molecular basis for the broad
spectrum of the antimalarial drug as well as for the species-specific differences in its effects.
This would allow us to develop a drug targeting cytochrome bc1 that would control the
emergence of resistant parasites. Furthermore, the other group has reported cocrystallization
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of a bovine cytochrome bc1 complex with the 4(1H)-pyridone class of inhibitors [81], which are
potent antimalarial agents in vivo [82, 83]. The X-ray structure demonstrates that these
inhibitors do not bind at the Qo site but rather at the Qi site. Differences in the inhibitor-binding
site to cytochrome bc1 complex would aid the rational drug designing for reducing the
emergence of inhibitor-resistant parasites and increasing selectivity against malaria parasites
toward novel treatments. In the future, in addition to binding site analysis using modalities
such as X-ray crystallography, we need to elucidate the molecular mechanisms explaining how
atovaquone resistance mutation is generated in the parasite mt genome.
5. 5-Aminolevulinic Acid (ALA): A new antimalarial candidate targeting
the mitochondrion
ALA is a precursor used in the biosynthesis of tetrapyrroles such as chlorophyll and heme.
The heme is an iron-containing complex macrocycle that plays a fundamental role in several
cellular processes, including oxygen transport and storage, mitochondrial respiratory chain,
and detoxification [84]. Generally, in mammalian cells, heme biosynthesis begins with ALA
formation by ALA synthase in the mitochondria from glycine and succinyl-CoA [85]. The next
four steps and three final steps occur in the cytosol and mitochondria, respectively. In cancer
cells, the uptake of a high concentration of ALA results in elevated levels of its metabolites,
particularly protoporphyrin IX (PPIX), due to insufficient activity of ferrochelatase [86]. The
PPIX accumulates in the mitochondria and consequently acts as a photosensitizer releasing
singlet oxygen and other reactive oxygen species (ROS), resulting in induction of cell death in
cancer. ALA therefore has been applied to the development of photodynamic diagnosis and
photodynamic therapy (PDT) of various cancers [87, 88].
Recently, all the enzymes of de novo heme-biosynthetic pathway have been characterized in
the human malaria parasite, P. falciparum [89-91]. In contrast to the mammalian enzymes of
heme biosynthesis, the parasite enzymes have unique localizations (Figure 5). The first
enzyme, ALA synthase, and the final two enzymes, protoporphyrinogen IX oxidase and
ferrochelatase (FC), localize to the mitochondrion. The enzymes that catalyze the intermediate
three steps—ALA dehydratase, porphobilinogen deaminase, and uroporphyrinogen decar‐
boxylase (UROD)—localize to the apicoplast, a nonphotosynthetic plastid. The next enzyme,
coproporphyrinogen III oxidase, is cytosolic. In addition, the catalytic efficiency of these
enzymes of the erythrocytic stages differs from that of mammalian enzymes: the enzymes
localizing to the apicoplast have very low catalytic efficacy [92]. Altogether, the properties of
the heme-biosynthetic pathway are remarkably different between malaria parasites and their
hosts. Hence, the heme-biosynthetic pathway has been recognized as a novel chemotherapeu‐
tic target in Plasmodium. Smith and Kain attempted PDT for human malaria parasites by adding
ALA to an in vitro culture [93]. The growth of Plasmodium was completely inhibited by 0.2 mM
ALA, followed by exposure to white light or by a higher concentration (2 mM) of ALA alone
without light exposure. This use of PDT is, unfortunately, clinically unrealistic because white
light cannot illuminate the inside of a malaria-infected patient’s body and the concentration
of 2 mM is extremely high to apply clinically.
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Figure 5. Heme biosynthesis of malaria parasites. The enzymes in the pathway are localized in the mitochondrion, api‐
coplast, and cytosol [89-91].
Our recent study resolved this issue: in the presence of ferrous ion, ALA efficiently inhibited
the in vitro growth of Plasmodium even without light exposure [94]. Because there was a
previous report on protection from malaria by elevated zinc protoporphyrin, which binds to
heme crystals to inhibit further crystallization to form hemozoin [95], we first investigated
effects of metal ions on growth inhibition by ALA using an in vitro culture system of P.
falciparum. Our results showed that treatment with 10 μM sodium ferrous citrate (SFC) and 0.2
mM ALA increased the growth inhibition to more than 50% when compared with that of 0.2
mM ALA alone. Notably, no other metal ions (e.g., zinc, lead, and copper) had such a syner‐
gistic effect, indicating that only ferrous compounds are synergistic with ALA.
Next, to determine heme intermediate, we analyzed the cell extract of the parasite using HPLC.
The extract contained three major intermediates: coproporphyrin I, coproporphyrin III (CPIII),
and PPIX. Unlike in cancer cells, CPIII was majorly accumulated in the apicoplast. Although
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its contribution to the parasite growth inhibition remains unknown, we believe that these
differences are due to the complicated heme-biosynthetic pathway (Figure 5) and life cycle of
Plasmodium (Figure 1). Moreover, PPIX, as is the case with cancer cells, accumulated mainly in
the mitochondrion. In PDT of cancer cells, PPIX acts as a photosensitizer releasing ROS,
resulting in extensive cellular damage and cell death [96]. This suggests that PPIX accumulated
in the parasite mitochondria is a factor contributing to the inhibition of parasite growth. Thus,
the parasite heme-biosynthetic pathway in the mitochondrion and apicoplast may be a
potential target of an antimalarial drug.
Recently, to confirm the efficacy of the combination of ALA and SFC (ALA/SFC) in treating
malaria using an animal model, we performed a preclinical drug evaluation of orally admin‐
istered ALA/SFC for the treatment of mice infected with the malaria parasite. ALA/SFC cured
50% of the Py17XL-infected mice, and the cured mice showed long-lasting humoral immune
responses to the same parasite strain and protection from homologous malarial infections [97].
ALA can be safe compound because a phase I clinical study has been successfully completed.
Considering the safety and mild antimalarial activities of ALA/SFC, a combination with an
available antimalarial drug, such as artemisinin or chloroquine, would be applicable for the
treatment of malaria.
6. Concluding remarks
The energy metabolism of malaria parasites has been considerably elucidated with accumu‐
lating data from several “omics” analyses. These data suggest that enzymes of the mitochon‐
drial TCA cycle and mtETC could be attractive targets for development of antimalarial drugs.
However, activity of these energy transduction pathways in the mitochondrion is considered
to be very low in the erythrocytic stages of the parasite. To address these possibilities, bio‐
chemical assay data are required. However, rigorous biochemical analysis of the parasite
mitochondrion, in which the TCA cycle and mtETC are present, is highly difficult because
intact and pure mitochondria cannot be obtained from the parasites thus far. As a consequence,
the malaria parasite mitochondrion needs to be purified to perform these future biochemical
studies. Biochemical data regarding the Plasmodium mitochondrion would shed light on the
details of mitochondrial enzyme behavior and help in the management of malaria.
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